Pulmonology

Laura Davis Joins VisionAir Solutions as Executive Director of Education

Retrieved on: 
Wednesday, February 14, 2024
Physician, FDA, Bachelor of Science, University of Michigan, Pulmonology, Business development, Lead, Dynasplint Systems, Stent, Patient, Western Michigan University, Anatomy, Disease, Software

CLEVELAND, Feb. 14, 2024 /PRNewswire/ -- VisionAir Solutions, a Cleveland, Ohio-based company that creates patient-specific airway stents announced that Laura Davis has joined its team as Executive Director of Education.

Key Points: 
  • Business development and sales leader Laura Davis joins VisionAir Solutions team as Executive Director of Education.
  • CLEVELAND, Feb. 14, 2024 /PRNewswire/ -- VisionAir Solutions, a Cleveland, Ohio-based company that creates patient-specific airway stents announced that Laura Davis has joined its team as Executive Director of Education.
  • Business development and sales leader Laura Davis joins VisionAir Solutions team as Executive Director of Education.
  • Laura joins VisionAir from an impressive background as a sales leader and education consultant.

Thirona receives FDA 510(k) Clearance for LungQ v3.0.0 Software to Power AI Analysis of Chest CT Images

Retrieved on: 
Monday, January 22, 2024
Technology, FDA, Hospitals, Clinical Trials, Health Technology, Software, Health, Pharmaceutical, Artificial Intelligence, Artificial intelligence, Patient, Hospital, Food and Drug Administration, Documentation, Map, Lung cancer, Pulmonology, COPD, Food, Fissure, Lung, Publication, Diagnosis, Physician

LungQ 3.0.0 is one of the only FDA-cleared solutions that is capable of using AI to automatically segment the pulmonary segments and subsegments found in the internal anatomy of the lung.

Key Points: 
  • LungQ 3.0.0 is one of the only FDA-cleared solutions that is capable of using AI to automatically segment the pulmonary segments and subsegments found in the internal anatomy of the lung.
  • Rita Priori, CTO at Thirona: “Our AI-based image analysis software LungQ is already used by interventional pulmonologist in Europe and Australia, aiding clinicians through procedures like bronchoscopic lung volume reduction and other interventions.
  • The FDA 510(k) cleared LungQ opens tremendous new opportunities for planning and performing localized treatments with maximum precision and accuracy.
  • To learn more about the LungQ software, please visit our website.

Parent Project Muscular Dystrophy Hosts 2024 Duchenne Healthcare Professionals Summit in Sanibel, Florida

Retrieved on: 
Wednesday, January 17, 2024
Hope, Research, Cardiology, APRN, Knowledge, Summit, Duchenne, PPMD, Neurology, Conference, Social, Blog, Pulmonology, Education, Nursing, Practitioner, Duchenne muscular dystrophy

WASHINGTON, Jan. 17, 2024 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD) , a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne) , will host its fifth in-person Duchenne Healthcare Professionals Summit in Sanibel, Florida, January 17-19.

Key Points: 
  • WASHINGTON, Jan. 17, 2024 /PRNewswire/ -- Parent Project Muscular Dystrophy (PPMD) , a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne) , will host its fifth in-person Duchenne Healthcare Professionals Summit in Sanibel, Florida, January 17-19.
  • Since the Summit's inception in 2018, the event has brought together thousands of healthcare providers, researchers, leaders in federal advocacy, and industry partners for discussion, collaboration, and connection.
  • "Our hope is continued investment in these efforts will lead to improved care for every person and every family living with Duchenne and Becker."
  • Additionally,  learnings from the 2024 Summit will be shared at PPMD's 30th Annual Conference this summer in Orlando, Florida.

IMVARIA Announces FDA De Novo Marketing Authorization of Fibresolve, an AI Biomarker in Lung Fibrosis, and the Adoption of Novel CPT Billing Codes by the American Medical Association

Retrieved on: 
Tuesday, January 16, 2024
FDA, Health Technology, Health Insurance, Technology, Radiology, Oncology, Professional Services, General Health, Medical Devices, Hospitals, Venture Capital, Artificial Intelligence, Biotechnology, Software, Health, Classification, Artificial intelligence, Death, Patient, MD, Idiopathic pulmonary fibrosis, American Medical Association, Pulmonology, Risk, Food, CPT, Disease, IPF, Pulmonary fibrosis, Biomarker, Nursing care plan, Lung, Diagnosis, Medical device

This signifies the first ever FDA authorization of a diagnostic tool of any type in lung fibrosis, and the first FDA Breakthrough-Designated AI diagnostic tool with simultaneously adopted CPT billing codes by the American Medical Association (AMA) in any disease.

Key Points: 
  • This signifies the first ever FDA authorization of a diagnostic tool of any type in lung fibrosis, and the first FDA Breakthrough-Designated AI diagnostic tool with simultaneously adopted CPT billing codes by the American Medical Association (AMA) in any disease.
  • “The FDA’s authorization of Fibresolve marks a significant milestone, not only for lung fibrosis patients, but also for the advancement of AI-based healthcare technologies.
  • Meanwhile, severe lung impairment and even death can happen within one to two years from the onset of lung fibrosis.
  • This new authorization builds on the past medical and scientific assessments that the FDA had previously completed in assigning Fibresolve Breakthrough Device Designation.

Chamblee Ryan P.C. Bolsters Firm Leadership with Three New Partners

Retrieved on: 
Wednesday, January 10, 2024
Legal, Professional Services, Practitioner, Partnership, Insurance, Cardiology, Mentorship, Employment, Pulmonology

The Dallas-based trial law firm of Chamblee Ryan PC is pleased to announce Tina Thomas , Jack G. B. Ternan , and Lynne Clarke have been named partners.

Key Points: 
  • The Dallas-based trial law firm of Chamblee Ryan PC is pleased to announce Tina Thomas , Jack G. B. Ternan , and Lynne Clarke have been named partners.
  • "We are delighted to welcome Tina, Jack, and Lynne to the partnership," says Bill Chamblee , managing partner of the firm.
  • "Their exceptional leadership and extensive experience in civil litigation have allowed us to enhance the firm's ability to anticipate and serve our clients' needs.
  • Chamblee Ryan PC is a Dallas-based trial firm representing insurance companies, medical professionals, transportation providers, healthcare institutions, and other businesses.

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

Retrieved on: 
Monday, January 8, 2024
Oncology, Health, Stem Cells, Neurology, Research, Science, Biotechnology, Virus, Cell, Cancer, Distinguishing, University, Biologic, Dove Medical Press, Neuroscience, UAB Hospital, Emory University, National academy, UAB, Glioblastoma, Radiation therapy, Neuro, Nature Biotechnology, Physician, Birmingham School of Law, Engineering, Neurosurgery, Potyvirus, Harvard Medical School, Supernova, Pulmonology, Hospital, Bangladesh Technical Education Board, University of Groningen, PNAS, Pharmaceutical industry

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.

Key Points: 
  • Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board.
  • “Calidi continues to expand our Scientific and Medical Advisory Board, adding leading physicians and scientists from the top cancer hospitals and research institutions in the United States,” said Allan Camaisa, CEO and Chairman of the Board of Calidi Biotherapeutics.
  • Dr. Chiocca is a faculty member at Harvard Medical School and leads a laboratory focused on developing novel genetic therapies for malignant brain tumors.
  • from the University of Tennessee and completed his residency and fellowship at UAB Hospital in Neurology and Neuro-oncology.

The Lung Center at Mercy Introduces Interventional Pulmonology

Retrieved on: 
Wednesday, January 3, 2024
Magnet, Weinberg Center, Neuromuscular disease, Body cavity, Multimedia, Division, Sister, Elective surgery, Respiratory disease, Sleep, COPD, The Sisters of Mercy, Lung cancer, Disease, Interventional pulmonology, Pulmonology, Pleural cavity, Cancer, Sarcoidosis, Health, Asthma, Glen Burnie, Maryland, IP, Patient, Mercy Hospital, Diagnosis, Radiation, Nursing

BALTIMORE, Jan. 2, 2024 /PRNewswire-PRWeb/ -- The Lung Center at Mercy Medical Center is expanding to include Interventional Pulmonology (IP), Albert J. Polito, M.D., Medical Director of The Lung Center and Chief of the Division of Pulmonary Medicine at Mercy, has announced. The expansion will essentially double the size of Mercy's current Lung Center with greater access for pulmonary patients.

Key Points: 
  • Interventional Pulmonology (IP) at Mercy Provides Minimally Invasive Procedures to Diagnose & Treat Lung Disease, Cancer / Mercy First in Maryland to Offer New Integrated Robotic Lung Navigational Technology
    BALTIMORE, Jan. 2, 2024 /PRNewswire-PRWeb/ -- The Lung Center at Mercy Medical Center is expanding to include Interventional Pulmonology (IP) , Albert J. Polito, M.D.
  • , Medical Director of The Lung Center and Chief of the Division of Pulmonary Medicine at Mercy, has announced.
  • Beyond the downtown location, Mercy Lung Center staff see patients at the Overlea, Lutherville, Reisterstown, and Glen Burnie sites of Mercy Personal Physicians.
  • Founded in 1874 by The Sisters of Mercy, Mercy is home to the acclaimed Weinberg Center for Women's Health & Medicine and the $400+ million, 20-story Mary Catherine Bunting Center.

The Inner Circle Acknowledges, Rocco Terrigno, MD as a Pinnacle Lifetime Member

Retrieved on: 
Friday, December 29, 2023
Rowan University, Family, Inner circle, Learning, Sleep, Pneumonia, Critical Care Medicine (journal), Internal medicine, Critical care, Medical degree, Health, MD, Education, Football, Respiratory failure, Asthma, Pleural disease, Cooper University Hospital, COVID-19, Assistant, Growth, Publication, Patient, Diagnosis, Memory, Nursing care plan, Cough, Pulmonology

MULLICA HILL, N.J., Dec. 29, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Rocco Terrigno, MD is acknowledged as a Pinnacle Lifetime Member for his contributions to the Pulmonologist and Critical Care field.

Key Points: 
  • MULLICA HILL, N.J., Dec. 29, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Rocco Terrigno, MD is acknowledged as a Pinnacle Lifetime Member for his contributions to the Pulmonologist and Critical Care field.
  • Dr. Rocco Terrigno a renowned pulmonologist and critical care intensivist, is making a significant impact in the field of respiratory medicine.
  • Dr. Terrigno's expertise encompasses a wide range of respiratory conditions, including cough, interstitial lung disease/sarcoid, COPD/emphysema, asthma, sleep disorders, lung nodules, pleural disease, respiratory failure, and COVID-19 pneumonia.
  • Currently, Dr. Terrigno serves as a fellowship-trained pulmonologist and critical care intensivist in the Department of Critical Care Medicine at Cooper University Hospital in Camden, New Jersey.

Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules

Retrieved on: 
Wednesday, November 29, 2023
Biotechnology, Health, Genetics, Clinical Trials, Oncology, Risk, Patient, Smoke, Malignancy, PPV, Anxiety, Lung cancer, Risk assessment, Diagnosis, Cancer, NPV, Pulmonology, Physician, Manuscript, Medical imaging

Veracyte, Inc. (Nasdaq: VCYT) announced that clinical validation data published in the journal CHEST show that the company’s Percepta Nasal Swab test determines lung cancer risk, with high accuracy, among people who currently smoke or have previously smoked and have lung nodules.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT) announced that clinical validation data published in the journal CHEST show that the company’s Percepta Nasal Swab test determines lung cancer risk, with high accuracy, among people who currently smoke or have previously smoked and have lung nodules.
  • Lung nodules are an early indicator of lung cancer and are typically found using computed tomography (CT) scans.
  • Results show that the Percepta Nasal Swab test is highly accurate in identifying patients with low-risk nodules (97% sensitivity, with 40% specificity).
  • “We believe our Percepta Nasal Swab test can be paradigm-changing in the evaluation of lung cancer risk among patients with lung nodules,” said Dr. Bulman.

Savara Reports Third Quarter Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Investment, Disease, Chemistry, Inc., Pulmonology, Research, APAP, Chair, Fine chemical, Savara

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2023 and provided a business update.

Key Points: 
  • Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2023 and provided a business update.
  • “We remain on track to report top line data from the pivotal, Phase 3 IMPALA-2 trial by the end of the second quarter 2024,” said Matt Pauls, Chair and CEO, Savara.
  • “In parallel, we are working to provide pulmonologists in the U.S. and Europe with a simple, accurate, no-cost, laboratory-based antibody blood test for aPAP.
  • As of September 30, 2023, the Company had cash, cash equivalents and short-term investments of ~$168.3 million and debt of ~$26.3 million.